Trial Profile

Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omalizumab (Primary)
Indications Asthma
Focus Biomarker; Therapeutic Use

Most Recent Events

26 Apr 2016 Results published in the Allergy
28 Feb 2012 Planned end date changed from 1 Jul 2012 to 1 Mar 2014 as reported by University Hospital Medical Information Network - Japan record.
20 Feb 2012 Additional lead trial investigator (Matsumoto H) identified as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com